Home>>Signaling Pathways>> Ox Stress Reagents>> Pro-Oxidant Activity>>SRS11-92

SRS11-92 (Synonyms: AA9)

Catalog No.GC40922

SRS11-92 is a ferroptosis inhibitor and a derivative of ferrostatin-1.

Products are for research use only. Not for human use. We do not sell to patients.

SRS11-92 Chemical Structure

Cas No.: 1467047-25-1

Size Price Stock Qty
1mg
$23.00
In stock
5mg
$102.00
In stock
10mg
$173.00
In stock
25mg
$357.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SRS11-92 is a ferroptosis inhibitor and a derivative of ferrostatin-1 . It inhibits ferroptotic cell death induced by erastin in HT-1080 human fibrosarcoma cells (EC50 = 6 nM). SRS11-92 (2 µM) inhibits iron-induced cell death in isolated mouse kidney proximal tubules, and fully protects rat oligodendrocytes from cystine deprivation-induced cell death in an in vitro model of periventricular leukomalacia when used at a concentration of 100 nM. It also increases survival of medium spiny neurons in rat corticostriatal brain slices in an in vitro model of Huntington's disease in a concentration-dependent manner. SRS11-92 (3 µM) increases production of reactive oxygen species (ROS) in L. major promastigotes in a time-dependent manner. It is selectively toxic to L. major promastigotes (LD50 = 3.34 µM) over U2OS human osteoblasts, RAW 264.7 macrophages, and intraperitoneal macrophages when used at a concentration of 80 µM.

Reviews

Review for SRS11-92

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SRS11-92

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.